Eribulin

Active ingredient: Eribulin Mesylate

In short: Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or

Forms & strengthsInjection: 1 mg/2 mL (0.5 mg/mL) eribulin mesylate is a clear, colorless, sterile solution in a single-dose vial.
LabelKindos Pharmaceuticals Co., Ltd.
Label updatedNov 13, 2026

What is Eribulin used for?

Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting

.

Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen .

Eribulin dosage

The recommended dose of eribulin mesylate injection is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

The recommended dose of eribulin mesylate injection in patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle .

The recommended dose of eribulin mesylate injection in patients with moderate hepatic impairment (Child-Pugh B) is 0.7 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle .

The recommended dose of eribulin mesylate injection in patients with moderate or severe renal impairment (creatinine clearance (CLcr) 15-49 mL/min) is 1.1 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle .

Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose.

Recommended dose delays

Do not administer eribulin mesylate injection on Day 1 or Day 8 for any of the following:– ANC < 1,000/mm3

– Platelets < 75,000/mm3

– Grade 3 or 4 non-hematological toxicities.

The Day 8 dose may be delayed for a maximum of 1 week.– If toxicities do not resolve or improve to ≀ Grade 2 severity by Day 15, omit the dose. – If toxicities resolve or improve to ≀ Grade 2 severity by Day 15, administer eribulin mesylate injection at a reduced dose and initiate the next cycle no sooner than 2 weeks later.

Recommended dose reductions

If a dose has been delayed for toxicity and toxicities have recovered to Grade 2 severity or less, resume eribulin mesylate injection at a reduced dose as set out in Table 1.

Do not re-escalate eribulin mesylate injection dose after it has been reduced.

Event Description | Recommended eribulin mesylate injection

Dose

Permanently reduce the 1.4 mg/m2 eribulin mesylate injection dose for any of the

following: | 1.1 mg/m2

ANC <500/mm3 for >7 days

ANC <1,000 /mm3 with fever or infection

Platelets <25,000/mm3

Platelets <50,000/mm3 requiring transfusion

Non-hematologic Grade 3 or 4 toxicities

Omission or delay of Day 8 eribulin mesylate injection dose in previous cycle for toxicity

Occurrence of any event requiring permanent dose reduction while receiving 1.1 mg/m2 | 0.7 mg/m2

Occurrence of any event requiring permanent dose reduction while receiving 0.7 mg/m2 | Discontinue eribulin mesylate injection

ANC = absolute neutrophil count. Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events(CTCAE) version 3.0.

Aseptically withdraw the required amount of eribulin mesylate injection from the single-dose vial and administer undiluted or diluted in 100 mL of 0.9% Sodium Chloride Injection, USP. …

How to take Eribulin β€” instructions & advice from the label

Advise the patient to read the FDA-approved Patient Labeling (Patient Information).

Neutropenia

Advise patients to contact their health care provider for a fever of 100.5Β°F or greater or other signs or symptoms of infection such as chills, cough, or burning or pain on urination

.

Peripheral Neuropathy

Advise patients to inform their healthcare providers of new or worsening numbness, tingling and pain in their extremities .

Embryo-Fetal Toxicity

Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy .

Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks after the final dose .

Advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose .

Lactation

Advise women not to breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose

. …

Warnings & precautions

Do not take this medicine if: None.

In Study 1, severe neutropenia (ANC < 500/mm3) lasting more than one week occurred in 12% (62/503) of patients with metastatic breast cancer, leading to discontinuation in <1% of patients. Febrile neutropenia (fever β‰₯38.5Β°C with Grade 3 or 4 neutropenia) occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia .

In Study 1, patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 Γ— ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels. Patients with bilirubin > 1.5 Γ— ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia.

In Study 2, severe neutropenia (ANC < 500/mm3) lasting more than one week occurred in 12% (26/222) of patients with liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 0.9% of patients treated with eribulin mesylate injection and fatal neutropenic sepsis in 0.9%

.

Monitor complete blood counts prior to each dose; increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration of eribulin mesylate injection and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days . Clinical studies of eribulin mesylate injection did not include patients with baseline neutrophil counts below 1,500/mm3.

In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients with metastatic breast cancer (MBC). Peripheral neuropathy was the most common toxicity leading to discontinuation of eribulin mesylate injection (5% of patients; 24/503) in Study 1. Neuropathy lasting more than one year occurred in 5% (26/503) of patients. …

Eribulin side effects

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

The following adverse reactions are discussed in detail in other sections of the labeling:

Neutropenia

Peripheral neuropathy

QT prolongation

In clinical trials, eribulin mesylate injection has been administered to 1963 patients including 467 patients exposed to eribulin mesylate injection for 6 months or longer. The majority of the 1963 patients were women (92%) with a median age of 55 years (range: 17 to 85 years). The racial and ethnic distribution was White (72%), Black (4%), Asian (9%), and other (3%).

Metastatic Breast Cancer

The most common adverse reactions (β‰₯25%) reported in patients receiving eribulin mesylate injection were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. The most common serious adverse reactions reported in patients receiving eribulin mesylate injection were febrile neutropenia (4%) and neutropenia (2%). The most common adverse reaction resulting in discontinuation of eribulin mesylate injection was peripheral neuropathy (5%).

The adverse reactions described in Table 2 were identified in 750 patients treated in Study 1 . …

Drug interactions

No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. Clinically meaningful differences in exposure (AUC) were not observed in patients with advanced solid tumors when eribulin mesylate injection was administered with or without ketoconazole (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and when eribulin mesylate injection was administered with or without rifampin (a CYP3A4 inducer) .

Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 enzymes or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations. Eribulin is not expected to alter the plasma concentrations of drugs that are substrates of these enzymes .

About this medicine

Eribulin mesylate injection contains eribulin mesylate, a microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okad

ai. The chemical name for eribulin mesylate is 11,15:18,21:24,28- Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt). It has a molecular weight of 826.0 (729.9 for free base). The empirical formula is C40H59NO11β€’CH4O3S. Eribulin mesylate has the following structural formula:

Eribulin mesylate injection is a clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. Each mL of solution contains 0.5 mg of eribulin mesylate (equivalent to 0.44 mg eribulin) in dehydrated alcohol (5% v/v) and water for injection (95% v/v). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label β€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9bfd8ac7-57e2-4c9d-add8-26502cfb54a8. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate